Gastric Gluten-Degradation Activity of PvP001

Digestive System Disease Clinical Trial

Official title:

A Phase I, First-in-Human Single Center Study in Healthy Adult Volunteers to Assess the Gastric Gluten-Degradation Activity of PvP001

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03594331
• Other study ID #: HUM00122254
• Status: Terminated
• Phase: Phase 1
• Start date: May 25, 2018
• Est. completion date: February 6, 2019

Study information

• Verified date: February 2019
• Source: University of Michigan
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single blind, dose escalating, placebo-controlled, crossover study of gluten-degrading drug PvP001 administered to healthy volunteers (age 18-64 years). Subjects will be randomized to one of three groups representing different levels of gluten exposure - low, medium, or high - in a single meal. Within each gluten exposure group, increasing doses of PvP001 (or placebo) will be administered.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 43
• Est. completion date: February 6, 2019
• Est. primary completion date: February 6, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 64 Years

Eligibility

Inclusion Criteria:

• Healthy volunteers;

• Able to maintain a gluten-free diet (GFD) for 24 hours prior to each of visits 1-4;

• Able to abstain from alcohol consumption 72 hours before and 72 hours after each visit;

• Able to tolerate the placement, presence, and manipulation of an oro-gastro-duodenal (OGD) tube;

• Women of child-bearing potential and men whose partners are women of child-bearing potential must be willing to use acceptable birth control for the duration of the study;

• Able to read and understand English;

• Able to provide written informed consent

Exclusion Criteria:

• Any condition or abnormality, current or past, that, in the opinion of the investigator, would compromise the safety of the subject, or would interfere with or complicate study procedures or assessments.

• No current or recent (within 14 days prior to each study visit, clinical laboratory testing, and ECG) use of over-the-counter or prescription medications via any route of administration, except for oral contraceptives for birth control (provided they have been used regularly for at least the past 3 months). Other medications used regularly at stable doses may be acceptable at the discretion of the study doctor.

• Current symptoms of congestion, upper respiratory tract infection, or acute illness

• Chronic viral infection or immunodeficiency condition

• Any female who is pregnant, planning to become pregnant during the study, or breast-feeding

• History of intolerance, hypersensitivity, or reaction to wheat or other grains, gluten, or any other food or food ingredient (including an additive or preservative) in the study meal;

• Receipt of an investigational medication within four weeks prior to the screening visit or from the screening visit through the final visit;

• Alcohol consumption >5 drinks/week or any alcohol consumption within the 72 hours prior to each study exposure visit or a positive breathalyzer test result at any study visit;

• Illicit or recreational drug use in the past 12 months or positive urine drug screen at the screening visit;

• History of smoking, nicotine, or tobacco use in the past 12 months;

• History or high risk of noncompliance with treatment or visits.

Related Conditions & MeSH terms

• Digestive System Disease
• Digestive System Diseases
• Gastrointestinal Diseases

Intervention

Drug:
• Low-dose PvP001
Low-dose PvP001
• Medium-dose PvP001
Medium-dose PvP001
• High-dose PvP001
High-dose PvP001
• Placebo
100 mL liquid with no drug

Locations

Country	Name	City	State
United States	Michigan Medicine	Ann Arbor	Michigan

Sponsors (2)

Lead Sponsor	Collaborator
Danielle Kim Turgeon	PvP Biologics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of treatment emergent adverse events	The number of treatment emergent adverse events at each dosage level	2 weeks from each exposure.
Primary	Percentage of treatment emergent adverse events	The percentage of treatment emergent adverse events at each dosage level	2 weeks from each exposure.
Primary	Side effects of study drug	Side effects are assessed by the PI using a 5-scale, 9-question Gastrointestinal Symptoms Questionnaire (GSQ) to be self-administered by the subject at 16 time-points throughout the five-visit (including screening) study. Each of the 9 questions will be given a numerical score (0-4 where 0 is none and 4 is very severe) and compared to baseline score and placebo scores any increase of >1 point over the average baseline and placebo score will be considered an AE and graded based on the severity reported.	12 months
Primary	Efficacy as measured by the lowest dose to degrade highest amount of gluten	The lowest dose of PvP001 that degrades the highest amount of gluten in a standardized study meal	12 months